«We need a reasonable balance between the development of generic and innovative drug products,» Kira Zaslavskaya spoke at the Russian Pharmaceutical Forum named after N.A. Semashko

Promomed 23 May 2022

Kira Zaslavskaya, Director for New Products of Promomed Group, discussed the balanced strategy for the development of new drugs and the formation of the company's drug portfolio in her speech during the session named «R&D market as an indicator of the current state of the Russian pharmaceutical industry: development prospects».


According to Kira Zaslavskaya, developments of both original and generic drugs should be based on an innovative approach. «Even if we are talking about generics, the addition of a new benefit is always in the center of our strategy. For example, increasing safety by improving the process,» the speaker said.

Over the past year, Promomed Group received approvals for several dozen medicines, including innovative ones. About a hundred more drugs are at different stages of research and development, or are already in the regulatory review stage.

Kira Zaslavskayasaid: «Let me continue talking about our strategy: we cooperate very closely with various R&D centers and research organizations and thanks to this close interaction we will be able to accelerate our developments. When we talk about new products, these can be, among all, next in class*drugs. By the example of a number of statins and drugs of other groups we see that the experience gained and the information about problems associated with the original molecule help to modify the chemical formula and obtain a drug with improved properties. On the other hand, process modification can provide improved tolerability or increase the efficacy of existing drugs and combinations.

Our company builds its strategy on the balance of creating such improved generics and innovative medicines that will expand the export potential, and, most importantly, ensure the security of pharmaceutical supply in our country. We can achieve this in close cooperation with scientific organizations, the medical community and other market participants, including pharmaceutical companies.»

Russian Pharmaceutical Forum named after N.A. Semashko is the largest event in the industry. Every year, representatives of well-known pharmaceutical companies, regulators and experts gather in Saint Petersburg to discuss current topics. This year, special attention was paid to the issues of working under sanctions, mechanisms for ensuring the stability of the pharmaceutical market and supporting drug availability, anti-crisis measures and prospects for the development of the domestic pharmaceutical industry.